Next, we used Next Generation Sequencing (NGS), to assess whether anti-C5 treatment affected molecular processes associated with dysmetabolism and inflammation in NASH in the liver. This evidence concerns the gene C5 and metabolic dysfunction-associated steatohepatitis.